Southern Star Energy Reports Year-End 2008 Reserves; Company Actively Evaluating Asset for Haynesville Potential

Monday June 30, 9:00 am ET

HOUSTON, June 30 /PRNewswire-FirstCall/ -- Southern Star Energy Inc. (OTC BB: SSEY.OB), a fast-growing E&P company with reserves and production from leases located in northern Louisiana, today announced its year-end May 31, 2008 estimated total proved reserves, and probable and possible reserves from its Sentell Field. The table below represents estimates attributable to interests owned by Southern Star Energy and only measure the Cotton Valley sands. The estimates for Southern Star's proved reserves were evaluated by H.J. Gruy, an independent reservoir-engineering firm, in accordance with SEC guidelines and from data provided by Southern Star. Gruy also evaluated the estimates of Southern Star's probable and possible reserves. Only proved reserves can be included in documents filed with the SEC

The estimated future net cash flows for the Company's proved, probable and possible reserves were calculated using $124.79 for oil, $2.10 for natural gas liquids (NGL) and $10.67 for natural gas, and held constant for the period 2008 through 2022.

Haynesville Shale Evaluation

The Company disclosed that it is actively evaluating the potential for drilling and producing natural gas from the Haynesville Shale, an emerging natural gas play, in its Sentell Field. Numerous vertical and horizontal wells have been drilled, logged and put into production from the Haynesville formation within a 30-mile radius of Southern Star's Sentell Field. Other operators have reported in their public disclosures that certain wells targeting the Haynesville formation have initial production rates of at least 8 million cubic feet per day with flowing casing pressure of 5,000 pounds per square inch. Southern Star's 5,700-acre Sentell Field has the potential for about 35 Haynesville wells positioned on 160-acre spacing. There are no probable or possible reserve estimates for the Haynesville Shale potential in Southern Star's year-end 2008 reserve report.

David Gibbs, Southern Star President and Chief Executive Officer said: "From a valuation perspective, the year-end 2008 reserve report offers a first glimpse into how quickly our drilling and completion work added reserves and established a foundation for our future. We are cash flow positive each month, a true testament to our work. Further, recent transactions by operators, notably EnCana's $457 million purchase of 88,920 acres in northern Louisiana and Chesapeake Energy's leasehold swap for prospective Haynesville acreage in East Texas for approximately $17,000 per acre are clear indicators of how the industry values the vast potential of the Haynesville Shale. We will begin a 10-well drilling program in August, and will start by drilling two Cotton Valley wells before drilling our first vertical Haynesville test well. We have an exciting opportunity to convert our proved undeveloped Cotton Valley inventory into cash flow as part of our 2008/2009 drilling program and we will perform an extensive technical evaluation of the Haynesville potential. We have an exciting 12 months ahead of us."

About Southern Star Energy

Southern Star Energy's strategy is to acquire under-drilled oil and natural gas leases with significant proven development drilling opportunities, and use all available technologies to increase the valuation of the acquired assets. This strategy reduces Southern Star's risk, allowing the Company to build free cash flow for strategic acquisitions. The Company owns a 40% working interest in approximately 5,700 acres in the Sentell Field, located in the heart of the known Cotton Valley trend north of Shreveport, La. To date, the Company has drilled five successful tests of the Cotton Valley sands, all of which are connected to the market, and producing revenues. The Company will embark on a 10-well development program in the third quarter of 2008, drilling for the Cotton Valley sand and Haynesville shale. Shareholders and prospective investors and analysts are encouraged to visit Southern Star Energy's website: http://www.ssenergyinc.com to learn more about the Company and the Cotton Valley Trend.

Cautionary Statements to Shareholders

Except for historical information contained herein, the statements in this Press Release are forward-looking statements that are made pursuant to the safe harbor provisions in the Private Securities Legislation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Southern Star Energy's actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things: volatility of natural resource prices; product demand; market competition and risks inherent in Southern Star Energy's operations. Southern Star makes undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable laws or regulatory policies.



For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

New Generation Biofuels Names Phillip R. Cherry, Jr. as Vice President, Engineering and Operations

Monday June 30, 9:47 am ET

Company Releases 2008 Achievements

HOUSTON, June 30 /PRNewswire-FirstCall/ -- New Generation Biofuels Holdings, Inc. (AMEX: GNB), a development stage renewable fuels provider, is pleased to announce Mr. Phillip R. Cherry Jr. has been appointed to the position of Vice President, Engineering and Operations. Cherry joins New Generation Biofuels as the company completes test burn programs with three leading utility companies and begins production to fulfill its first fuel contract for a power generation customer who has chosen New Generation Biofuels as its renewable energy option.

Cherry will be directly responsible for the site selection and construction of the first commercial scale biofuel plant for New Generation Biofuels. Cherry, recently with the ethanol producer VeraSun, brings a wealth of biofuel technology knowledge to his role in overseeing all aspects of the design, development, construction, and operation of New Generation Biofuels' production facilities.

David A. Gillespie, President and CEO of New Generation Biofuels, said, "We are excited to have Mr. Cherry on-board, and we believe his talents will complement the direction and growth of New Generation Biofuels.

The company has reached several key milestones within the past 12 months. These include successful test burn programs with three leading utility scale power producers. The successful test burns led to its first sales contract to supply up to 1.7 million gallons annually of biofuel to a major west coast independent power producer. Now is the time to bring Phillip Cherry on board to manage operational growth."

"Our power generation customer response to New Generation Biofuel is excellent," states Gillespie. "Overall emissions are lower, including Nitrogen Oxide (NOx) reductions in excess of 40% and our biofuel can be burned without significant modification to existing facilities. We have also been working towards reducing reliance on food source feedstocks by utilizing recycled vegetable oils in many of our test burns.

"On April 15, 2008, New Generation Biofuels was listed on the American Stock Exchange. We believe this listing will not only provide greater recognition for New Generation Biofuels in the investment community, but also a more liquid, efficient market for our stock, reinforcing our objective of maximizing shareholder value," stated David Gillespie.

On Friday, June 27th, New Generation Biofuels joined the Russell Microcap Index, which provides for the inclusion of our common stock in a number of growth and value style funds tied to the Russell Microcap Index.

About New Generation Biofuels Holdings, Inc.

New Generation Biofuels is a development stage renewable fuels provider. We hold an exclusive license for North America, Central America and the Caribbean to commercialize proprietary technology to manufacture alternative biofuels from vegetable oils and animal fats that we intend to market as a new class of biofuel for power generation, heavy equipment, marine use and as heating fuel. We believe our proprietary biofuel can provide a cheaper, renewable alternative energy source with significantly lower emissions than traditional fuels. Our business model calls for establishing direct sales from manufacturing plants that we may purchase or build and sublicensing our technology to qualified licensees.

Forward Looking Statements

This news release contains forward-looking statements. These forward-looking statements concern our operations, prospects, plans, economic performance and financial condition and are based largely on our current beliefs and expectations. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such forward-looking statements. The risks and uncertainties related to our business include all the risks attendant a development stage business in the volatile energy industry, including, without limitation, the risks set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2007. All forward-looking statements included in this news release are based on information available at the time of the release. We are under no obligation to update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:
David Gillespie, President & CEO
New Generation Biofuels, Inc.
713-973-5720

Rob Schatz
Wolfe Axelrod Weinberger Associates, LLC
212-370-4500

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

Quantum Schedules Fiscal 2008 Fourth Quarter Financial Results Conference Call

Monday June 30, 9:30 am ET

IRVINE, Calif., June 30 /PRNewswire-FirstCall/ -- Quantum Fuel Systems Technologies Worldwide, Inc., (NasdaqGM: QTWW) will hold a conference call to announce its Fiscal 2008 Fourth Quarter financial results. The call will be held on Monday, June 30, 2008 at 1:30pm Pacific Time (4:30pm Eastern Time).

If you are interested in participating, call the following number ten minutes prior to the starting time: (706) 643-3625, Conference ID # 53823470. An operator will check your name and organization. You will be asked to wait until the call begins.

For those of you unable to join us for this earnings call, a playback of this call will be available via telephone approximately two hours after the call until Tuesday, July 15, 2008 at 1:30 p.m. Pacific time. The number for this service is (800) 642-1687 or (706) 645-9291. The call will also be available on the Company's Investor Relations web page by Tuesday, July 15, 2008:

http://www.qtww.com/about/investor_information/conference_calls/index.php

The call will also be available at its investor relations counsel's webpage at http://www.redchip.com.

For assistance with this call, please call Elaine Lovre at (206) 315-8242.

About Quantum:

Quantum Fuel Systems Technologies Worldwide, Inc., a fully integrated alternative energy company, is a leader in the development and production of advanced propulsion systems, energy storage technologies, and alternative fuel vehicles. Quantum's portfolio of technologies includes advanced lithium-ion battery systems, electronic controls, hybrid electric drive systems, hydrogen storage and metering systems, and alternative fuel technologies that enable fuel efficient, low emission hybrid, plug-in hybrid electric, fuel cell, and alternative fuel vehicles.

Quantum's powertrain engineering, system integration, vehicle manufacturing, and assembly capabilities provide fast-to-market solutions to support the production of hybrid and plug-in hybrid, hydrogen-powered hybrid, fuel cell, alternative fuel, and specialty vehicles, as well as modular, transportable hydrogen refueling stations. Quantum's customer base includes automotive OEMs, dealer networks, fleets, aerospace industry, military and other government entities, and other strategic alliance partners.

Quantum has also formed a new company with Fisker Coachbuild, LLC, which is called Fisker Automotive, Inc. Fisker Automotive will offer a range of environmentally friendly premium cars, incorporating Quantum's proprietary high-performance plug-in-hybrid electric vehicle architecture, known as "Q-Drive", into a unique chassis that will enable optimizing the performance and vehicle dynamics.

More information can be found about Quantum's products and services at http://www.qtww.com.

Forward Looking Statements

Except for historical information, the statements, expectations, and assumptions contained in the foregoing press release are forward-looking statements. Such forward-looking statements include, but are not limited to, the Company's expectations regarding statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Such statements are subject to a number of risks and uncertainties, and actual results could differ materially from those discussed in any forward-looking statement. Reference should also be made to the risk factors set forth from time to time in the Company's SEC reports, including but not limited to those contained in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended April 30, 2008. The Company does not undertake to update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.

For more information regarding Quantum, please contact:

Dale Rasmussen
Investor Relations
Email: DRasmussen@qtww.com
+1-206-315-8242

Investor Relations:

RedChip Companies, Inc.
Sanford Diday
1-800-REDCHIP (733-2447, Ext. 115)
info@redchip.com
http://www.redchip.com

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

RXi Pharmaceuticals Included in Russell Microcap Index

Monday June 30, 7:30 am ET

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (NasdaqCM: RXII), a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it has been added to the Russell Microcap Index as part of Russell Investments' annual reconstitution of its family of U.S. indexes.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

Dr. Tod Woolf, President and Chief Executive Officer of RXi, said, "We are pleased that we have been added to the Russell Microcap Index. We believe that the exposure gained from our listing has the potential to increase our visibility within the investment community."

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4.4 trillion in assets currently are benchmarked to them. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

Annual reconstitution of Russell indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization to create the Russell 3000® Index and Russell Microcap.

About Russell

Russell Investments aims to improve financial security for people by providing strategic advice, world-class implementation, state-of-the-art performance benchmarks, and a range of institutional-quality investment products. With more than $213 billion in assets under management, Russell serves individual, institutional and advisor clients in more than 40 countries. Russell provides access to some of the world's best money managers. It helps investors put this access to work in corporate defined benefit and defined contribution plans, and in the life savings of individual investors.

Founded in 1936, Russell is a subsidiary of Northwestern Mutual Life Insurance Company. Headquartered in Tacoma, Wash., U.S., Russell has principal offices in Amsterdam, Auckland, Johannesburg, London, Melbourne, New York, Paris, San Francisco, Singapore, Sydney, Tokyo and Toronto. For additional information, visit http://www.russell.com.

About RXi Pharmaceuticals

RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and potential commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. RXi Pharmaceuticals' rxRNA™ compounds are distinct from the siRNA compounds used by many other companies developing RNAi therapeutics and are believed by the Company, based on its internal research, to be up to 100 times more active than conventional siRNA (depending on the target site), nuclease resistant and readily manufactured. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi-based therapeutics market with its accomplished scientific advisors, including Dr. Craig Mello, recipient of the 2006 Nobel Prize for his co-discovery of RNAi, a management team that is experienced in developing RNAi products, and a strong early intellectual property position. For additional information about the Company, go to: http://www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, plan and future development of RXi Pharmaceutical Corporation's products and technologies. These forward-looking statements about future expectations, plans and prospects of the development of RXi Pharmaceutical Corporation's products and technologies involve significant risks, uncertainties and assumptions, including the risk that the development of our RNAi-based therapeutics may be delayed or may not proceed as planned and we may not be able to complete development of any RNAi-based product, the risk that the FDA approval process may be delayed for any drugs that we develop, and the possibility that other companies or organizations may assert patent rights that prevent us from developing our products. Actual results may differ materially from those RXi Pharmaceuticals Corporation contemplated by these forward-looking statements. RXi Pharmaceuticals Corporation does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

Carbon Sciences Announces Joint Research Agreement With University and Its Research Team

Monday June 30, 5:59 am ET

Research Team From Finland Is Considered Among the World's Leaders in Carbon Mineralization Research

SANTA BARBARA, CA--(MARKET WIRE)--Jun 30, 2008 -- Carbon Sciences Inc. (Other OTC: CABN.OB), the developer of a breakthrough technology to transform harmful carbon dioxide (CO2) into high value, earth-friendly products, today announced that it has signed a joint research agreement with Abo University, Finland.

The research team led by Professor Ron Zevenhoven at Abo University is considered among the world's leaders in carbon transformation research. Carbon transformation, technically referred to as carbon mineralization, is a process in which CO2 is combined with rock minerals to produce a solid carbonate. Due to the unique geology of Finland, underground sequestration of CO2 is not an economically viable option. Therefore, an important option for CO2 mitigation in Finland is carbon transformation.

Derek McLeish, the company's CEO, commented, "Carbon Sciences is aligning with various international strategic partners. With the completion of this agreement, we'll be working with the world's premier researchers in CO2 carbon transformation."

"We are pleased to be researching carbon mineralization technologies with Carbon Sciences," stated Professor Ron Zevenhoven of Abo University. "Our research associates have studied and worked with many promising approaches to permanently capturing CO2 in the last decade. We are delighted to be working with Carbon Sciences, a visionary company in the industry."

Professor Zevenhoven, formerly of Helsinki University, has been at the forefront of this research for many years. Geological sequestration or underground storage is one of the proposed solutions for mitigating CO2 emissions. However, in many instances it is simply not feasible, geographically or economically, to bury CO2 underground. Long term environmental and human risks and their associated costs argue instead for other technical solutions. Carbon Sciences' technology transforms CO2, using a carbon mineralization process, into high value products used in everyday life.

About Carbon Sciences Inc.

Carbon Sciences Inc. is developing a breakthrough technology to transform harmful carbon dioxide (CO2) emissions from human created sources, such as power plants and industrial factories, into high value, earth-friendly products. The initial application of our patent-pending technology is targeted at a multi-billion dollar market. We are developing a proprietary process to transform CO2 emissions into a high value chemical compound, currently used in the production of paper, pharmaceuticals and plastics. Unlike existing methods of production, our process will be carbon neutral, use less energy and result in a lower cost product. To learn more about Carbon Sciences, please visit our website at http://www.carbonsciences.com.

Safe Harbor Statement

Matters discussed in this press release contain statements that look forward within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such statements that look forward. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the statements that look forward contained herein, and while expected, there is no guarantee that we will attain the aforementioned anticipated developmental milestones. These statements that look forward are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

Fisker's Quantum-Powered Luxury Hybrid Sports Sedan Featured in U.K. CAR Magazine

Friday June 27, 9:30 am ET

IRVINE, Calif., June 27 /PRNewswire-FirstCall/ -- Quantum Fuel Systems Technologies Worldwide, Inc. (NasdaqGM: QTWW), today announced that the Quantum-powered Fisker Karma, a high-performance hybrid sports sedan built through a partnership with green automaker, Fisker Automotive, Inc., is featured in the July 2008 edition of the CAR Magazine, a U.K. publication focusing on trends and technology in the automotive industry.

"We're very excited to see the car featured in such a popular publication," said Alan P. Niedzwiecki, president and CEO of Quantum. "We continue to see growing interest in the Karma, both from traditional car enthusiasts and eco-conscious drivers around the world."

The five-page article by Ben Oliver is part of a feature entitled, "Cars to Save the Car," and highlights the unique features of the Karma, as designed by the CEO of Fisker Automotive, Henrik Fisker, who formerly designed the Aston Martin's DB9 and BMW's Z8 roadster. The piece details Fisker's success in creating a car that delivers high-speed performance, luxury style, and zero-emissions, all at a reasonable price tag for a luxury sports sedan of US$80,000. The Fisker Karma, as Oliver notes, is one of the first green technology vehicles "to go on sale in big numbers, at a viable price and to make a major dent on emissions and oil use."

Quoting Henrik Fisker in the article, Oliver writes: "'Usually, enthusiasts are the first to buy a new car, environmentalists the last. We've united the two. You don't get as much reaction in a cool sports car now; people don't look at you and say 'lucky guy.' That's why you see movie stars in Priuses. People are just amazed and surprised that they can now have a truly sexy environmental car. This is the car they've been waiting for. Consumers are ahead of the car companies' here.'"

The car's power comes from Quantum Technologies' innovative Q-Drive, which is a hybrid propulsion system configured with a small gasoline engine used solely to power an electric generator that charges a lithium-ion battery pack. The advanced propulsion system takes the Karma from 0 to 60 mph in 5.8 seconds, reaching speeds in excess of 125 mph. Quantum's Q-Drive technology will provide a base for all future derivatives from Fisker Automotive.

In addition to supplying the Karma's advanced electric drive motor and lithium-ion battery and control systems, Quantum also supplies the car's regenerative braking system, generator, power inverters and the electronics and software systems. Quantum's German engineering partner, Asola, supplies the Karma's rooftop solar panels, which provide an additional power source for the car.

Fisker expects to deliver 100 of the luxury hybrids by the end of 2009 with full production commencing in 2010.

For more information, visit http://www.qtww.com or http://www.fiskerautomotive.com.

About Quantum Fuel Systems Technologies Worldwide, Inc.

Quantum Fuel Systems Technologies Worldwide Inc., a fully integrated alternative energy company, is a leader in the development and production of advanced propulsion systems, energy storage technologies, and alternative fuel vehicles. Quantum's portfolio of technologies includes advanced lithium-ion battery systems, electronic controls, hybrid electric drive systems, hydrogen storage and metering systems, and alternative fuel technologies that enable fuel efficient, low emission hybrid, plug-in hybrid electric, fuel cell, and alternative fuel vehicles. Quantum's power-train engineering, system integration, vehicle manufacturing, and assembly capabilities provide fast-to-market solutions to support the production of hybrid, plug-in hybrid, hydrogen-powered hybrid, fuel cell, alternative fuel, and specialty vehicles as well as modular, transportable, hydrogen refueling stations. Quantum's customer base includes automotive OEMs, dealer networks, fleets, aerospace industry, military and other government entities, and other strategic alliance partners. For more information, visit http://www.qtww.com.

About Fisker Automotive, Inc.

Keeping with the company's mantra of "Simply World Class," Fisker Automotive and its retailers will offer a customer experience second to none. All retailers will be housed in eco-friendly facilities and will offer consumers a unique personal approach, including the ability to ask questions via video conference with an expert at Fisker Automotive headquarters and flexible scheduling based on consumer availability.

Fisker Automotive is a privately owned car company with Henrik Fisker serving as the CEO. Fisker Coachbuild, LLC will be the exclusive design house for Fisker Automotive through the entire range of product development. Additional executive team members include Vic Doolan, Board Member FA & Director of Retail Development; Alan Niedzwiecki, CEO Quantum Technologies & Board Member FA; Bernhard Koehler, COO; Thomas Fritz, Director of Engineering; and production design by Alexander Klatt, formerly of BMW and Mark Clarke formerly of Porsche. This experienced team will help Fisker Automotive lead the future and redefine automotive design by creating the ultimate eco-chic car -- cars that marry unparalleled style with environmental consciousness.

Forward-Looking Statements: Except for historical information, the statements, expectations, and assumptions contained in the foregoing press release are forward-looking statements. Such forward-looking statements include, but are not limited to, the Company's expectations regarding expected future revenues and operating results; future opportunities for Quantum; the Company's ability to fulfill orders in the future; and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Such statements are subject to a number of risks and uncertainties, and actual results could differ materially from those discussed in any forward-looking statement. Factors that could cause actual results to differ materially from such forward-looking statements include, among other factors, prevailing market conditions; the Company's ability to design and market automotive products; the Company's ability to meet customer specifications and qualification requirements; availability of component parts and raw materials that meet the Company's requirements; and the Company's ability to source alternative materials and suppliers. Reference should also be made to the risk factors set forth from time to time in the Company's SEC reports, including but not limited to those contained in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended April 30, 2007. The Company does not undertake to update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.

Contact:

At the Company:

Dale Rasmussen
Quantum Fuel Systems Technologies Worldwide, Inc.
Investor Relations
Email: DRasmussen@qtww.com
1-206-315-8242

Investor Relations:

RedChip Companies, Inc.
Sanford Diday
1-800-REDCHIP (733-2447, Ext. 115)
info@redchip.com
http://www.redchip.com

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

GeoPharma Reports Second Consecutive Quarter of Record Revenues

Thursday June 26, 4:01 pm ET

LARGO, Fla.--(BUSINESS WIRE)--GeoPharma, Inc. (NasdaqCM: GORX) announced today a second consecutive quarter of record revenues reporting an unprecedented $23,890,000 for the fiscal fourth quarter ended March 31, 2008. The highest quarterly revenue total in the Company history represents a 31% jump sequentially versus the 3rd quarter ended December 31, 2007 and a 68.5% increase versus the corresponding quarter a year ago. GeoPharma finished the fiscal year on March 31, 2008 with total revenues of $57,893,000.

Commenting on the financial report GeoPharma CEO Mihir K. Taneja said, "We continue to enjoy the top line progress the company has been exhibiting due primarily to our Dynamic Health Products acquisition, which has been accretive on every level in the short time since the deal was consummated. We look forward to the continued integration of Dynamic to further bolster our financial goals. It is with great umbrage that we report that our bottom line number is not where we expected it to be at this time. This is mainly attributable to several factors including increased SG&A expenses, increased advertising expense in our branded products division and a small increase in expenses related to the Pharma division. It is our firm belief that 2009 will be a hallmark year for the Company, we remain confident that our two Antibiotic facilities will be granted approval in the near-term. The progress of our Ovarian Cancer Diagnostic Device is going extraordinarily well and ahead of schedule. Our core business is tracking higher again and we fully expect a return to profitability within fiscal year 2009, with anticipated revenues in excess of $100 million."

Year End and Q4 Highlights

• Total revenues for the fiscal year ended March 31, 2008 was $57.9 million, a 3.2% decrease compared to $59.8 million for the Fiscal year ended March 31, 2007.
• Total selling, general and administrative ("SGA") expenses were $20.8 million for the fiscal year 2008 as compared $15.6 million, a 33.3% increase.
• Research and development ("R&D") expenditures for the fiscal year totaled approximately $1.6 million all of which was charged as an expense to operations as compared to approximately $1.5 million of R&D expense for the fiscal year ended March?31, 2007.
• Net loss for fiscal 2008 was $(7.4) million as compared to net income of $2.2 million for fiscal 2007.
• Total revenues for the fourth quarter ended March?31, 2008 grew to $23.9 million, a 66.0% increase as compared to the fourth quarter ended March?31, 2007 of $14.4 million.
• Gross profits were $4.6 million for the March 2008 quarter, a 10.3% increase compared to the $4.2 million March 2007 quarter.
• Research and development ("R&D") expenditures for the three months ended March?31, 2008 totaled approximately $608,000 all of which was charged as an expense to operations as compared to $567,000 of R&D expense for March 2007 quarter.
• Net loss for the March quarter 2008 was $(2.8) million as compared to net income of $534,000 in the March quarter 2007.

Conference Call Information

GeoPharma will host a conference call to discuss results on Thursday June 26, at 4:35 p.m. (ET) with CEO, Mihir Taneja, Senior VP/CFO, Carol Dore-Falcone and Alexander Nachman Director of Corporate Communications. Participants may dial in to register the day of the conference call 5 minutes before, or 4:30 p.m. ET. The dial in number for participants is 1-877-407-8031 (Toll Free) or 1-201-689-8031 (For International Callers).

The Conference call can also be accessed via webcast by utilizing the following link: http://www.vcall.com/CustomEvent/webcast.asp?ID=131486.

Participants in the conference call will be able to submit questions in writing over the internet. Conference call replay: will be available by webcast until: 09/27/2008 or by telephone replay until: 07/10/2008. The telephone replay numbers are 1-877-660-6853 or 1-201-612-7415 The following Pass Codes will be required for either style of replay: Account# 286 and Conference ID# 289732.

About GeoPharma, Inc.:

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.

GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.

Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities.

For further information visit the "For Investors" section of the GeoPharma website at www.geopharmainc.com.

Forward Looking Statements

This press release may contain statements, which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.

For Further Information, Contact:

RedChip Companies, Inc.

500 Winderley Place, Suite 100, Maitland, FL 32751,

(800) 733-2447,Fax: (407) 644-0758,

info@redchip.com

Western Standard Energy Corp. Comments on US Govt Report: Up to 6.2 TCF of Undiscovered Biogenic Gas Resources in Montana

Thursday June 26, 9:00 am ET

WILLISTON, N.D.--(BUSINESS WIRE)--Western Standard Energy Corp., (OTC BB: WSEG.OB) (hereafter "Western Standard" or "the Company"), an oil and gas exploration company, is pleased to announce an additional drilling permit from the Bureau of Land Management, a department of the U.S. Department of the Interior. The permit was granted to its operating partner, Coastal Petroleum, for a third well on the Starbuck East prospect in Valley County, Montana. The permit pertains to a well location at Federal 1-13, which is a step-out well from the exploration well at Federal 1-19 drilled to approximately 1,000 feet in October, 2007, which currently remains on hold for completion and testing due to Federal land restrictions on access and usage until July 15 based on environmental and wildlife obligations.

The permit's issuance came prior to the recent results of a US Geological Survey ("USGS") report that assessed the Undiscovered Biogenic Gas Resources in the North-Central Montana Province where Western Standard has a 50% interest in the Starbuck East Prospect, an area of approximately 42,000 acres in Valley County, Montana.

According to the USGS report produced in May and released in June of 2008, "Application of a geology-based assessment methodology by the U.S. Geological Survey resulted in an estimated mean of 6,192 billion cubic feet of shallow biogenic (continuous) undiscovered gas in the North-Central Montana Province". The assessment has confirmed the potential for almost 4 trillion cubic feet of gas (TCF) from both the Judith River (around 500' depth) and the Eagle Sandstone (around 1,100' depth) formations.

Dan Bauer, President and CEO of Western Standard Energy stated: "Western Standard's immediate plans include testing both the Judith River and Eagle zones for productivity upon completion of the Federal 1-19 in the next month. We are pleased with the USGS assessment as it reinforces our intentions to explore and develop within the North-Central Montana region.

"The results of the assessment can be downloaded from the US Geological Survey website at: http://pubs.usgs.gov/fs/2008/3036/

The Company released an Operational Update on Starbuck East in May of 2008, which can be viewed at the Company website.

About Western Standard Energy Corp. (the "Company")

Western Standard Energy Corp. is an independent oil and gas exploration company. The Company has secured and is developing a portfolio of oil and gas properties in Montana and North Dakota, in the United States. The Company is a publicly traded company and trades on the OTC BB under the ticker symbol: WSEG. Shareholders are invited to contact corporate communications toll free at (888) 956-7843 for further information or to visit our website at www.western-standard.com.

Western Standard Energy Corp.

Dan Bauer, President

Forward-Looking Statements

Statements in this news release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. Forward-looking statements in this news release include that the Company will complete Federal 1-19, that it will drill Federal 1-21 and Federal 1-13, that the Company will complete further land acquisitions, and that there is up to 6,192 billion cubic feet of biogenic gas in the State of MT, or up to 4 trillion cubic feet of gas in the Judith River and Eagle formations as referenced in the recent USGS assessment. It is important to note that actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include the uncertainty of the requirements demanded by environmental agencies, the Company's ability to raise financing for operations, breach by parties with whom we have contracted, inability to maintain qualified employees or consultants, competition for equipment, inability to obtain drilling permits, potential delays or obstacles in drilling operations and interpreting data, and the likelihood that no commercial quantities of gas are found or recoverable. Readers should also refer to the risk disclosures outlined in the Company's quarterly reports on Form 10-QSB, annual reports on Form 10-KSB and the Company's other disclosure documents filed from time-to-time with the Securities and Exchange Commission available at www.sec.gov.

Cautionary Note to U.S. Investors

The United States Securities and Exchange Commission ("SEC") permits oil and gas companies, in their filings with the SEC, to disclose only proved reserves that a company has demonstrated by actual production or conclusive formation tests to be economically and legally producible under existing economic and operating conditions. We use certain terms?in this document, such as "estimated technically recoverable oil " that the SEC's guidelines may prohibit us from including in filings with the SEC. U.S. investors are urged to consider closely the disclosure in our annual report on Form 10-KSB and quarterly reports on Form 10-QSB available from us or the SEC.

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

ZAGG Inc. Introduces invisibleSHIELD for New Apple iPhone 3G

Thursday June 26, 6:00 am ET

Industry Leader in Protective Film Covering First to Offer Scratch-Proof Protection for Latest iPhone

SALT LAKE CITY--(BUSINESS WIRE)--ZAGG Inc. (OTC BB: ZAGG.OB), the industry leader in providing protective film coverings for personal electronics, announced the availability of an invisibleSHIELD™ for the newly released Apple iPhone 3G. The invisibleSHIELD is made from a patented adhesive film exclusive to ZAGG for the purpose of protecting high-performance electronic devices, such as mobile phones, PDAs, gaming devices and laptops.

ZAGG's invisibleSHIELD for the iPhone 3G has been available for pre-order at ZAGG.com for three weeks, receiving over 50,000 orders to date. ZAGG is excited to announce that they will begin shipping June 27, 2008, two full weeks prior to the July 11, 2008 launch of the new iPhone.

"We strive to be the first to market with our designs, and our customers know they are getting the best when they choose the invisibleSHIELD," said Robert G. Pedersen II, President and CEO of ZAGG. "Apple is known for creating beautifully designed electronics and the invisibleSHIELD is the perfect solution for protecting them while maintaining their sleek look and not covering them up with a bulky case."

The ultra-tough material used to create the invisibleSHIELD was originally utilized by the U.S. military to protect helicopter blades from wind, sand and the wear and tear of high-speed travel. Combining this military-grade scratch protection with precision-cut designs, the invisibleSHIELD, backed by a lifetime guarantee, allows customers to use their electronics without the fear of scratches or nicks.

To see ZAGG's full catalog or to purchase online, please visit www.ZAGG.com.

About ZAGG Inc.:

ZAGG Inc. designs, manufactures, and distributes protective clear coverings and accessories for consumer electronic and hand-held devices, worldwide. ZAGG's flagship brand, the invisibleSHIELD, is a protective, high-tech film covering, designed for iPods, laptops, cell phones, digital cameras, PDAs, watch faces, GPS systems, gaming devices, and other items. The patent-pending invisibleSHIELD application is the first scratch protection solution of its kind on the market, and has sold over one million units. Currently, ZAGG offers over 2,500 precision pre-cut designs with a lifetime replacement warranty through online channels, resellers, college bookstores, Mac stores and mall kiosks. The company continues to increase its product lines to offer additional electronic accessories to its tech-savvy customer base, as well as an expanded array of invisibleSHIELD products for other industries. For more information please visit the company's web site at www.ZAGG.com.

Safe Harbor Statement

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in filings made by the company with the Securities and Exchange Commission.

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

XsunX Thin Film Solar Module Manufacturing Facility Update

Thursday June 26, 6:00 am ET

ALISO VIEJO, Calif., June 26 /PRNewswire-FirstCall/ -- XsunX, Inc. (OTC BB: XSNX.OB), a solar technology Company engaged in the build-out of its multi-megawatt thin film photovoltaic (TFPV) solar manufacturing facilities, announced today that the manufacturing facility in Portland, Oregon is ready for inspection. The current tenants notified XsunX that demolition is ahead of schedule by 3 weeks and a walk through is scheduled for the week of July 7th. XsunX will as a result take possession of the manufacturing facility at least 2 weeks ahead of schedule.

The company recently released a detailed mid-year update on business development and the multi-megawatt thin film solar module factory initiative. For any shareholders that may have missed this report you can access it at either the company or U.S. Securities Exchange Commission (SEC) website:

XsunX Web site: http://www.XsunX.com

SEC Website: http://www.sec.gov/Archives/edgar/data/1039466/ 000114420408036498/v118104_8k.htm (Due to the long URL, copy and paste link into browser.)

Safe Harbor Statement: Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

RedChip Visibility Initiates Research Coverage On Legend Media

Wednesday June 25, 12:02 pm ET

ORLANDO, Fla., June 25, 2008 (PRIME NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc., has initiated coverage on Legend Media, Inc. (OTC.BB: LEGE.OB), a first-mover planning to develop a broad advertising network to capitalize on China's emerging consumer culture.

Gaurav Aggarwal, MBA, RedChip Research Analyst, reported:

``LEGE is continuously acquiring exclusive rights to sell advertisement spots, or ad space, for a large number of radio stations throughout China and has successfully established strong relationships with radio broadcasting networks and leading advertising agencies in China that will provide access to key sales outlets and additional advertising assets.

``We believe if LEGE is able to successfully consummate its business plans, it could potentially offer China's largest portfolio of commercial radio time slots, market research, and key advertising agency relationships. The Company is refining its business strategy to grow, both organically into new cities and provinces as well as through the acquisition of existing smaller businesses in other Chinese provinces,'' he continued.

``We are initiating coverage of LEGE with a 'Speculative Buy' rating and a 12-month target price of $6.10,'' Aggarwal concluded.

To receive a complimentary copy of the RedChip Visibility Initial Research Report for LEGE, please visit:

http://www.redchip.com/visibility/about.asp?page=vreport&reportid=118&from=06252008pr

About RedChip Companies

RedChip Companies is an international, small-cap research and financial public relations firm with offices in Maitland, Florida; Bangalore, India; and Beijing, with affiliates in New York and San Diego. RedChip delivers concrete, measurable results for its clients through its extensive national and international network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research(tm), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, RedChip Internet TV(tm), and RedChip Radio(tm). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/productsandservices.asp

``Discovering Tomorrow's Blue Chips Today''(tm)

The RedChip Companies, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2761

Disclosure

None of the profiles issued by RedChip Companies constitutes a recommendation for any investor to purchase or sell any particular security or that any security is suitable for any investor. Any investor should determine whether a particular security is suitable based on the investor's objectives, other securities holdings, financial situation needs, and tax status. Legend Media, Inc. paid RedChip Visibility, a division of RedChip Companies, Inc., $36,000 for RedChip Visibility Program services, which included the preparation of this equity research report. RedChip Companies is currently engaged by this company to provide investor relations services. Legend Media agreed to pay RedChip Companies, Inc. a fee of $7,500 in cash per month and 150,000 shares of common stock under Rule 144 for twelve (12) of these services. RedChip Companies, Inc. employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. To the fullest extent permissible under applicable law, RedChip Companies, Inc. will not be liable to you or anyone else for the quality, accuracy, completeness, reliability, or timeliness of this information.

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

India Globalization Capital Subsidiary Awarded $12.75M Construction Contract by Sahara Infrastructure and Housing

Wednesday June 25, 9:26 am ET

Company increases backlog of orders from $349M to about $362M

BETHESDA, Md., June 25 /PRNewswire-FirstCall/ -- India Globalization Capital, Inc. (Amex: IGC - News), a company developing infrastructure in India, announced that its subsidiary, Sricon Infrastructure, was awarded a $12.75 million construction contract by Sahara Infrastructure and Housing, for civil engineering and construction in a 106-acre planned township in Nagpur City, India.

The contract, which includes structural construction of thirteen buildings, will commence in the quarter ending September 2008 and will continue for a period of two years. This latest contract increases the company's backlog of orders from approximately $349 million to approximately $362 million.

"With the three recent contract wins of around $120 million, we have reaffirmed our guidance for the fiscal year ending March 31, 2009 of revenue between $110 million to $125 million and earnings between $7 million to $9 million, not including any one-time or non cash charges," said Ram Mukunda, CEO of IGC. We are trading around 5 times earnings while our peer group is trading at much higher multiples. With the current backlog we expect to grow over 30% for fiscal year ending March 31, 2010," he continued.

Mukunda added, "We are currently also pursuing around $347 million worth of new contracts, which, if we are successful in winning, would increase our 2010 projections considerably."

Sricon, based in Nagpur, the largest city in central India, has engaged in civil engineering construction activities since 1974. This construction contract adds to and diversifies the company's pipeline of activities, which include road widening projects and industrial infrastructure development of power plants and water supply systems, as well as mining and quarrying activities. Sricon is qualified technically and through prior experience to bid on contracts valued up to $116M per contract.

About IGC

Based in Bethesda, Maryland, IGC operates through two infrastructure companies in India, Sricon Infrastructure Private Limited ("Sricon") and Techni Bharathi, Limited ("TBL"). IGC owns sixty-three percent of Sricon and seventy-seven percent of TBL. IGC has three core competencies: 1) highway and other heavy construction, 2) mining & quarrying and 3) civil construction and engineering of high temperature plants. The Company's medium term plans are to expand each of these lines of business.

Most of IGC's operations are based in India. The company has offices in Maryland, Mauritius, Nagpur, Cochin, Delhi and Bangalore. Copies of the Form S-3 and IGC's other filings with the SEC containing information about IGC, our Indian operations and other relevant documents, are available at no charge at the SEC's Internet site (http://www.sec.gov). For more information about IGC, visit the company's web site at www.indiaglobalcap.com.

Forward-Looking Statements:

This press release may contain forward-looking statements. These statements reflect management's current views and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, expressed or implied in these statements. Factors, which could cause actual results to differ, relate to: (i) the ability of the parties to successfully win new contracts, execute on contracts and business plan, (ii) our ability to raise additional capital and the structure of such capital including the exercise of warrants, and (iii) changes in the exchange rate between the US dollar and the Indian Rupee. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Other factors and risks that could cause or contribute to actual results differing materially from such forward looking statements have been discussed in greater detail in the company's definitive proxy statement and supplement filed with the SEC and incorporated by reference into the Form S-3.

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

RedChip Visibility Issues First Quarter 2008 Research Update On BioSolar

Monday June 23, 1:01 pm ET

ORLANDO, Fla., June 23, 2008 (PRIME NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc., today announced that it has issued a first quarter 2008 research update on BioSolar, Inc. (OTC BB: BSRC.OB), a company developing innovative bio-based components for use in the manufacture of solar cells that will replace traditional, petroleum-based components.

Neha Bhargava, MBA, RedChip Research Analyst, reported:

``BSRC is progressing toward the manufacturing stage and has decided to sign manufacturing agreements for production of its BioBacksheet(tm) product. In mid-June 2008, BSRC selected Rowland Technologies Inc. as its partner for initiating the full-scale production of its BioBacksheet. We believe the Company will be able to reach the manufacturing stage by the end of 2008, and accordingly, we project BSRC to report revenue in 2008, albeit of marginal magnitude.''

``In late April 2008, the Company began shipping BioBacksheet samples to a select group of manufacturers in several regions of the country for evaluation purposes. Since then, some other large U.S. and global solar manufacturers have requested BioBacksheet samples for evaluation, indicating keen interest in the product. Such widespread demand for the samples reaffirms our viewpoint that the Company will receive positive market response for BioBacksheet samples,'' she continued.

``We expect BSRC will be on a revenue-generating platform in late 2008 as the Company receives positive market responses from the samples delivered. We reiterate our 'Speculative Buy' rating on BSRC stock and raise our initial 12-month target price from $0.80 to $0.90,'' Bhargava concluded.

To receive a complimentary copy of the RedChip Visibility Research Report for BSRC, please visit:

http://www.redchip.com/visibility/about.asp?page=vreport&reportid=116&from=06232008pr

About RedChip Companies, Inc.

RedChip Companies is an international, small-cap research and financial public relations firm with offices in Maitland, Florida; Bangalore, India; and Beijing, with affiliates in New York and San Diego. RedChip delivers concrete, measurable results for its clients through its extensive national and international network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research(tm), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, RedChip Internet TV(tm), and RedChip Radio(tm). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/productsandservices.asp

The RedChip Companies, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2761

``Discovering Tomorrow's Blue Chips Today''(tm)

Disclosure

None of the profiles issued by RedChip Companies, Inc. constitutes a recommendation for any investor to purchase or sell any particular security or that any security is suitable for any investor. Any investor should determine whether a particular security is suitable based on the investor's objectives, other securities holdings, financial situation needs, and tax status. BioSolar, Inc. paid RedChip Visibility, a division of RedChip Companies, Inc., $30,000 for RedChip Visibility Program services, which included the preparation of this equity research report. To the fullest extent permissible under applicable law, RedChip Companies, Inc. will not be liable to you or anyone else for the quality, accuracy, completeness, reliability, or timeliness of this information.

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

RedChip Visibility Initiates Research Coverage On Elephant Talk Communications

Tuesday June 24, 1:46 pm ET

ORLANDO, Fla., June 24, 2008 (PRIME NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc., today announced it has initiated research coverage on Elephant Talk Communications, Inc. (OTC.BB: ETAK.OB), an international telecom and multimedia content distributor.

Vivek Srivastava, MBA, RedChip Research Analyst, reported:

``ETAK has created a unique business model that is designed to provide traditional telecommunication (i.e., voice) and media distribution (i.e., streaming) services primarily to B2B customers and has developed a turnkey mobile platform that allows their client base to rapidly capture the explosive wireless subscriber market. The services are delivered through a streamlined network telecom with ETAK's proprietary network of switches and monitoring software, all of which are strategically positioned on four continents.

``ETAK's strategy has been to build on its fixed-line infrastructure while developing a mobile infrastructure to become a fully aggregated Mobile Virtual Network Enabler (MVNE) with its own integrated platforms, switches, and networks. ETAK will continue to build upon its network by adding MVNE capabilities at lower investment costs while spreading its overhead to give it a competitive advantage over traditional MVNEs and other competitors. The Company's business model is targeted to attract and facilitate customers who want to enter the mobile market but lack the financial resources and/or technical capabilities to invest in the needed infrastructure. ETAK's first MVNE contract with T-Mobile in the Netherlands is expected to be operational in June 2008, and management expects to add two to three national MVNE set-ups every year, over the next couple of years.

``We believe synergies from the integration of ETAK's recent acquisitions coupled with new partnerships and agreements, along with an expanding array of products and services, will result in higher revenue generation for the Company, particularly in the high-growth markets of the Middle East, Africa, and Asia where penetration levels are still low. Nonetheless, there is fierce competition in the industry, but the fact that ETAK provides a one-stop shop proposition for its clients with integrated billing solutions and has a low-cost structure serves to differentiate the Company from its competitors. Also, the Company's ability to exploit the new opportunities in the Mobile Virtual Network Operator (MVNO) segment further validates our belief,'' Srivastava continued.

``We recommend this investment with a rating of 'Speculative Buy' and a 12-month target price of $2.40,'' he concluded.

To receive a complimentary copy of the RedChip Visibility Initial Research Report for ETAK, please visit:

http://www.redchip.com/visibility/about.asp?page=vreport&reportid=117&from=06242008pr

For more information about Elephant Talk, visit http://www.redchip.com/visibility/investor.asp?symbol=ETAK

About RedChip Companies, Inc.

RedChip Companies is an international, small-cap research and financial public relations firm with offices in Maitland, Florida; Bangalore, India; and Beijing, with affiliates in New York and San Diego. RedChip delivers concrete, measurable results for its clients through its extensive national and international network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research(tm), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, RedChip Internet TV(tm), and RedChip Radio(tm). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/productsandservices.asp.

``Discovering Tomorrow's Blue Chips Today''(tm)

The RedChip Companies, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2761

Disclosure

None of the profiles issued by RedChip Companies, Inc. constitutes a recommendation for any investor to purchase or sell any particular security or that any security is suitable for any investor. Any investor should determine whether a particular security is suitable based on the investor's objectives, other securities holdings, financial situation needs, and tax status. Elephant Talk Communications, Inc. (ETAK) paid RedChip Visibility, a division of RedChip Companies, Inc., $50,000 for RedChip Visibility Program services, which included the preparation of this equity research report. RedChip Companies, Inc. is currently engaged by this company to provide investor relations services. ETAK agreed to pay RedChip Companies, Inc. a fee of $23,000 in cash per month and $45,000 in total value of equivalent shares of common stock under Rule 144 for four months of these services. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. This report is not a recommendation of a solicitation to purchase or sell any security, nor does it constitute investment advice. To the fullest extent permissible under applicable law, RedChip Companies, Inc. will not be liable to you or anyone else for the quality, accuracy, completeness, reliability, or timeliness of this information.

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

RXi Pharmaceuticals Announces $8.7 Million Private Placement

Tuesday June 24, 1:05 pm ET

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation ("RXi") (NasdaqCM: RXII), today announced that it has entered into definitive agreements with institutional investors to issue and sell an aggregate of 1,073,299 shares of its common stock in a private placement at a price of $8.12 per share, resulting in aggregate gross proceeds of approximately $8.7 million. Jefferies & Company acted as the lead placement agent and Natixis Bleichroeder Inc., Broadpoint Securities Group, Inc. and Griffin Securities, Inc. acted as the co-placement agents for the private placement. The private placement is expected to close on or around Wednesday, June 25, 2008, subject to customary closing conditions.

The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes, including building its pipeline of rxRNA™ compounds for potential alliances, internal development and collaborations.

The securities issued in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws, and accordingly may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state and securities laws. The company has agreed to file a registration statement with the Securities and Exchange Commission registering for resale the shares of common stock issued in this private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful.

About RXi Pharmaceuticals

RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and potential commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. RXi Pharmaceuticals' rxRNA™ compounds are distinct from the siRNA compounds used by many other companies developing RNAi therapeutics and are believed by the Company, based on its internal research, to be up to 100 times more active than conventional siRNA (depending on the target site), nuclease resistant and readily manufactured. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi-based therapeutics market with its accomplished scientific advisors, including Dr. Craig Mello, recipient of the 2006 Nobel Prize for his co-discovery of RNAi, a management team that is experienced in developing RNAi products, and a strong early intellectual property position. www.rxipharma.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, plan and future development of RXi Pharmaceutical Corporation's products and technologies. These forward-looking statements about future expectations, plans and prospects of the development of RXi Pharmaceutical Corporation's products and technologies involve significant risks, uncertainties and assumptions, including the risk that the development of our RNAi-based therapeutics may be delayed or may not proceed as planned and we may not be able to complete development of any RNAi-based product, the risk that the FDA approval process may be delayed for any drugs that we develop, and the possibility that other companies or organizations may assert patent rights that prevent us from developing our products. Actual results may differ materially from those RXi Pharmaceuticals Corporation contemplated by these forward-looking statements. RXi Pharmaceuticals Corporation does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

Webcast Alert: Fourth Quarter 2008 Earnings Conference Call

Tuesday June 24, 12:00 pm ET

LARGO, Fla.--(BUSINESS WIRE)--GeoPharma Inc. (GORX) announces the following Webcast:

What: Fourth Quarter 2008 Earnings Conference Call

When: June 26, 2008 @ 4:35 PM Eastern

Where: http://www.investorcalendar.com/ClientPage.asp?ID=131486 (Webcast participants will be able to submit questions in writing over the net)

How: Live over the Internet -- Simply log on to the web at the address above or access by telephone at: 877-407-8031 (Toll Free) or 201-689-8031 (International).

For additional information Contact: Alexander Nachman, 727-471-0781 x 243, IR@Geopharmainc.com

If you are unable to participate during the live webcast, the call will be available for replay at:

http://www.investorcalendar.com/ClientPage.asp?ID=131486 or

http://www.investorcalendar.com/

Or by Telephone at 877-660-6853 (Toll Free) or 201-612-7415 (International) by using replay pass codes:

Account #: 286 and Conference ID #: 289732, until July 10, 2008

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.

GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.

Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities.

For further information visit the "For Investors" section of the GeoPharma website at www.geopharmainc.com .

This press release may contain statements, which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

Worldwide Energy and Manufacturing Receives $4,747,970 in Funding

Tuesday June 24, 9:30 am ET

SOUTH SAN FRANCISCO, CA and SHANGHAI, CHINA--(MARKET WIRE)--Jun 24, 2008 -- Worldwide Energy and Manufacturing USA, Inc. (OTC BB: WEMU.OB), a U.S.-based China manufacturing company for customers in the industries of aerospace, wireless telecommunications, medical equipment, automobiles and solar energy, is pleased to announce that on June 23, 2008 Worldwide Energy and Manufacturing USA, Inc. (the "Company") received subscriptions for the sale of an aggregate of $4,747,970.50 or 1,055,103 shares of common stock (the "Shares"). Concurrently with the issuance of the Shares, the Company also issued an aggregate of 685,817 Series A Warrants of the Company (the "Series A Warrants") and an aggregate of 369,286 Series B Warrants of the Company (the "Series B Warrant"). The Series A Warrants are exercisable for a period of 24 months from closing at an exercise price of $7.00 per share. The Series B Warrants are exercisable for a period of 36 months from the closing at an exercise price of $9.00 per share. The Series A and Series B Warrants provide the investors with full ratchet anti-dilution protection with relation to the exercise price of the warrant for a period of 18 months from the closing. RedChip Capital LLC and RedChip Securities Inc. were the placement agents for the capital raise.

Mr. Jimmy Wang, CEO of Worldwide, stated, "We will use these funds to complete our De Chuang factory acquisition, to expand our energy division and due a further acquisition. In addition, these funds will grow the company to new records for growth and profitability."

About Worldwide Energy and Manufacturing USA, Inc.

Worldwide Energy and Manufacturing USA, Inc. ("Worldwide"), headquartered in South San Francisco, is a 14-year-old engineering-oriented firm specializing in international manufacturing for solar modules, electronics, mechanical and fiber optic products. Worldwide is also a direct manufacturer of die-casting and electronics components. The company's worldwide customer base includes the industries of solar energy, wireless telecommunications, aerospace, automobiles and medical equipment. Worldwide also manufactures components for the following industries: instrumentation, machinery, tools, home electrical solutions and electronic parts (such as electronic toys) and energy. Subsidiaries include Shanghai Intech Electro Mechanical Products Co. Ltd., Shanghai Intech Electronics Manufacturing Co. Ltd. and Shanghai Intech Precision Mechanical Products Manufacturing Co. Ltd., located in Shanghai, China.

For further information on Worldwide Energy and Manufacturing USA, Inc., please visit www.wwmusa.com. You may register to receive Worldwide Energy and Manufacturing USA, Inc.'s future press releases or request to be added to the Company's distribution list by contacting John Ballard.

Forward-Looking statements:

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performances, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events, or otherwise.

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

New Generation Biofuels Set to Join Russell Microcap Index

Tuesday June 24, 8:30 am ET

HOUSTON, June 24 /PRNewswire-FirstCall/ -- New Generation Biofuels Holdings, Inc. (AMEX: GNB), a renewable fuels provider which just listed on the American Stock Exchange (AMEX) in mid-April, will join the Russell Microcap Index when Russell Investments reconstitutes its family of U.S. indexes on Friday, June 27th, after the market closes, according to a preliminary list of additions posted Friday on www.russell.com.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

"We are extremely pleased to have been selected to the Russell Index," said Cary J. Claiborne, Chief Financial Officer. "Inclusion increases our visibility to a broader investment community." Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4.4 trillion in assets currently are benchmarked to them.

Annual reconstitution of Russell indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization to create the Russell 3000 Index and Russell Microcap. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

Total returns data for the Russell Microcap and other Russell Indexes is available at http://www.russell.com/Indexes/performance/daily_total_returns_us.asp.

About New Generation Biofuels Holdings, Inc.

New Generation Biofuels is a renewable fuels provider. We hold an exclusive license for North America, Central America and the Caribbean to commercialize proprietary technology to manufacture alternative biofuels from vegetable oils and animal fats that we intend to market as a new class of biofuel for power generation, heavy equipment, marine use and as heating fuel. We believe our proprietary biofuel can provide a cheaper, renewable alternative energy source with significantly lower emissions than traditional fuels. Our business model calls for establishing direct sales from manufacturing plants that we may purchase or build and sublicensing our technology to qualified licensees.

About Russell

Russell Investments aims to improve financial security for people by providing strategic advice, world-class implementation, state-of-the-art performance benchmarks, and a range of institutional-quality investment products. With more than $213 billion in assets under management, Russell serves individual, institutional and advisor clients in more than 40 countries. Russell provides access to some of the world's best money managers. It helps investors put this access to work in corporate defined benefit and defined contribution plans, and in the life savings of individual investors.

Founded in 1936, Russell is a subsidiary of Northwestern Mutual Life Insurance Company. Headquartered in Tacoma, Wash., U.S., Russell has principal offices in Amsterdam, Auckland, Johannesburg, London, Melbourne, New York, Paris, San Francisco, Singapore, Sydney, Tokyo and Toronto.

Forward Looking Statements

This news release contains forward-looking statements. These forward-looking statements concern our operations, prospects, plans, economic performance and financial condition and are based largely on our current beliefs and expectations. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such forward-looking statements. The risks and uncertainties related to our business include all the risks attendant a development stage business in the volatile energy industry, including, without limitation, the risks set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2007. All forward-looking statements included in this news release are based on information available at the time of the release. We are under no obligation to update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:
David Gillespie, President & CEO
New Generation Biofuels, Inc.
713-973-5720

Rob Schatz
Wolfe Axelrod Weinberger Associates, LLC
212-370-4500

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com

Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discove

Tuesday June 24, 8:00 am ET

SOUTH EASTON, Mass., June 24 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (NasdaqCM: PBIO) today announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) Grant (2R44GM079059-02) from the National Institutes of Health (NIH). The Grant will help fund continuing experiments directed towards the development and commercialization of novel, automated, and reproducible methods for the extraction of clinically important protein biomarkers, subcellular molecular complexes, and organelles (such as mitochondria) from cells and tissues using the Company's patented pressure cycling technology ("PCT"). The Grant is for a total of $850,000, to be billed over two years. Final paperwork is expected to be completed within the next several weeks; work on the project is expected to begin shortly thereafter. Dr. Feng Tao of PBI is the Principal Investigator.

Over the past 18 months, the Company and its collaborators have generated initial feasibility data in the use of PCT to extract protein biomarkers, subcellular molecular complexes, and organelles. These studies were partially funded by a $149,000 NIH SBIR Phase I Grant (1R43GM079059-01) awarded PBI in 2006. The new SBIR Phase II Grant is intended to fund additional development in these areas, with the expectation that these studies will ultimately lead to the release of a new, commercially available PCT-based system, with validated protocols, end-user kits, and other consumables intended for the extraction of clinically important protein biomarkers, subcellular molecular complexes, and organelles.

Dr. Bruce S. Kristal of the Department of Neurosurgery, Brigham and Women's Hospital (Boston), and the Company's primary collaborator in the new SBIR Phase II Grant, commented: "Mitochondria are best known for their role in energy production, but they also play critical roles in cellular response to signals, regulating gene expression, and controlling cell death. Mitochondrial dysfunction has been implicated in diabetes, cancer, neurodegenerative disorders, stroke, head injury, and other disorders. As such, mitochondria are recognized as a major potential drug target. We will be testing and developing the ability of PBI's PCT Sample Preparation System ("PCT SPS") to increase the standardization of mitochondrial isolations and to increase yield and quality of mitochondria from tissues difficult to work with, such as muscle and brain. We also will examine the ability of the PCT SPS to facilitate biochemical studies of mitochondrial constituents that are often otherwise limited by solubility concerns. If successful, this work would facilitate drug development in the above diseases, generally aid research into the roles that mitochondria play in these diseases, and potentially facilitate some research directly into personalized medicine."

Dr. Alexander Lazarev, Vice President of Research and Development at PBI, stated: "This new Grant will allow us to continue our efforts in the development and commercialization of standard, automated, and reproducible PCT-dependent methods for obtaining mitochondria and other organelle preparations. Such methods could prove invaluable in both the simplification and in the acceleration of drug discovery and development. We are also pleased that we will have the opportunity to work with Dr. Kristal, as we regard him as a leading expert in the area of mitochrondrial function and related diseases."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and higher) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the finalization of paperwork with the NIH and work commencement; the reported effectiveness of PCT in cell lysis and isolation of subcellular molecular complexes, including organelles; the speed, reproducibility, quality, and simplicity of sample preparation using PCT compared with current sample preparation methods for subcellular fractionation; the adoption of PCT over other sample preparation methods; the expectation that the Company's studies, when continued with the proceeds of the Grant, will lead to a new, commercially available PCT-based system, with validated protocols, end-user kits, and other consumables; and the possibility that these studies may facilitate drug development, generally aid research into the roles that mitochondria play in certain diseases, and potentially facilitate some research directly into personalized medicine. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: the possibility that for unforeseen reasons, the final documentation for the Grant is not completed or the funds under the Grant are not released to the Company; that due to unforeseen technological difficulties, the Company may be unable to develop a new commercially successful PCT-based system for the extraction of protein biomarkers; the possibility that due to the nature of the research being performed, other laboratories and scientists may not find the use of PCT to be as advantageous as demonstrated in the SBIR Phase I report and anticipated in the SBIR Phase II grant proposal; that due to unforeseen future competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751,
(800) 733-2447,Fax: (407) 644-0758,
info@redchip.com